Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 60290-087

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 60290-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Umedica Laboratories Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Sacubitril And Valsartan Structure)

Chemical structure of Sacubitril and Valsartan, illustrating the molecular configuration of the active ingredients corresponding to this combination drug.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 1)

A chart showing the geometric mean ratio and 90% confidence interval for various coadministered drugs relative to a reference. The chart lists drugs on the vertical axis and displays change relative to reference on the horizontal axis, with data points for AUC (filled circles) and Cmax (open circles). Drugs included are furosemide, warfarin, digoxin, carvedilol, levonorgestrel, ethinyl estradiol, amlodipine, HCTZ, metformin, atorvastatin, and sildenafil.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 2)

A pharmacokinetic comparison chart showing geometric mean ratios and 90% confidence intervals for AUC and Cmax of LBQ657 and Valsartan across various population subgroups, including renal and hepatic impairment, age, sex, and race. The chart measures changes relative to reference values for these parameters.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 3)

A set of three Kaplan-Meier cumulative failure rate graphs from the PARADIGM-HF study comparing Sacubitril and Valsartan versus Enalapril. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations. Figure B depicts time to occurrence of cardiovascular death. Figure C shows time to first occurrence of heart failure hospitalizations. Each graph includes hazard ratios with 95% confidence intervals and the number of patients at risk over time in days since randomization.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 4)

A forest plot chart comparing the hazard ratios of Sacubitril and Valsartan versus Enalapril across various subgroups. The subgroups include age, gender, weight, race, region, NYHA class, estimated GFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, and heart failure history. The x-axis ranges from 0.25 to 4, indicating relative outcomes between the two treatments.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 5)

A line graph depicting the mean number of total heart failure hospitalizations and cardiovascular death events per 100 patients over time in days since randomization, comparing Sacubitril and Valsartan versus Valsartan alone from the PARAGON-HF study. The graph shows two lines, with the Sacubitril and Valsartan group consistently having fewer events over approximately 1440 days.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 6)

A forest plot figure comparing rate ratios between Sacubitril and Valsartan versus Valsartan across multiple patient subgroups including age, gender, race, region, diabetic status, LVEF, and others. The horizontal axis represents the rate ratio ranging approximately from 0.25 to 2, with individual subgroup estimates and 95% confidence intervals plotted as squares and lines, respectively, summarizing comparative effectiveness outcomes.*

FDA Label Image

Image Description (Sacubitril And Valsartan Figure 7)

A dual line chart comparing hazard ratios between Sacubitril and Valsartan versus enalapril (PARADIGM-HF) and Sacubitril and Valsartan versus valsartan (PARAGON-HF). The x-axis shows left ventricular ejection fraction at screening (%) and the y-axis shows hazard ratio, with hazard ratio lines and 95% confidence intervals displayed for each comparison group.*

FDA Label Image

"image Description" (Sacubitril And Valsartan 24mg 26mg 60s Bottle Label)

Label for Sacubitril and Valsartan Tablets 24 mg/26 mg, film-coated oral tablets in a 60-tablet package. The product is manufactured by Umedica Laboratories Pvt. Ltd., India, and distributed by Umedica Laboratories USA Inc. The label includes storage instructions, dosage information referencing prescribing information, and a barcode alongside regulatory details.*

FDA Label Image

"image Description" (Sacubitril And Valsartan 49mg 51mg 60s Bottle Label)

Label for Sacubitril and Valsartan Tablets 49 mg/51 mg film-coated tablets. The label includes NDC 60290-086-01 and states the product is manufactured by Umedica Laboratories Pvt. Ltd. in India and distributed by Umedica Laboratories USA Inc. It contains 60 tablets per package, storage instructions, and a medication guide URL.*

FDA Label Image

"image Description" (Sacubitril And Valsartan 97mg 103mg 60s Bottle Label)

Label for Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets by Umedica Laboratories USA Inc. The label includes storage instructions, dosage guidance reference, manufacturer and distributor information, barcode, and a 60-tablet count. Manufactured in India, with a medication guide URL provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.